KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Kyverna Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$5.83+0.16 (+2.82%)

Close on Oct 19, 2026

Market cap: $355.03M
P/E (TTM): –
Dividend yield: –

Kyverna Therapeutics, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Cash & Equivalents	124	97	35	–
Short-Term Investments	155	189	23	–
Cash & Short-Term Investments	279	286	58	–
Prepaid Expenses & Other	3.70	4.62	3.12	–
Total Current Assets	283	291	61	–
Property, Plant & Equipment	1.55	3.35	2.33	–
Gross Property, Plant & Equipment	5.30	7.02	4.81	–
Accumulated Depreciation	-3.75	-3.67	-2.49	–
Operating Lease Right-of-Use Assets	3.57	6.47	6.49	–
Other Long-Term Assets	4.90	2.84	3.36	–
Total Assets	294	305	75	–
Accounts Payable	5.31	4.62	4.36	–
Current Portion of Leases	3.66	3.16	1.96	–
Total Current Liabilities	36	34	20	–
Long-Term Debt	25	–	–	–
Long-Term Leases	0.32	4.16	5.24	–
Operating Lease Liabilities	3.98	7.32	7.20	–
Total Liabilities	62	38	26	–
Total Debt	25	–	–	–
Preferred Stock	0	0	–	–
Common Stock	0.00	0	–	–
Additional Paid-In Capital	657	530	4.64	–
Retained Earnings	-425	-264	-136	–
Comprehensive Income & Other	0.10	0.11	0.00	–
Shareholders' Equity	232	267	-13	-74
Total Equity	232	267	-13	-74
Total Liabilities & Equity	294	305	75	–
Shares Outstanding(shares)	60	43	1.25	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -64.7%

Financial strength

Current ratio: 9.06
Debt to equity: 0.15
Debt to assets: 11.3%
Cash to current liabilities: 139.5%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 2.14
Dividend yield: –